0001178913-22-001181.txt : 20220321 0001178913-22-001181.hdr.sgml : 20220321 20220321060446 ACCESSION NUMBER: 0001178913-22-001181 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220318 FILED AS OF DATE: 20220321 DATE AS OF CHANGE: 20220321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maryles Joel Michael CENTRAL INDEX KEY: 0001850990 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 22754134 MAIL ADDRESS: STREET 1: 5 ATZMON ST. CITY: HASHMONAIM STATE: L3 ZIP: 7312700 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 zk2227511.xml X0306 4 2022-03-18 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001850990 Maryles Joel Michael 5 ATZMON ST. HASHMONAIM L3 7312700 ISRAEL 1 0 0 0 American Depositary Shares 2022-03-18 4 P 0 500 4.32 A 500 D American Depositary Shares 2022-03-18 4 P 0 500 4.36 A 1000 D Option to Purchase American Depositary Shares 3.53 2022-03-07 4 A 0 6820 0 A 2032-03-07 American Depositary Shares 6820 6820 D Option to Purchase American Depositary Shares 27.26 2021-04-19 4 A 0 11884 0 A 2031-04-19 American Depositary Shares 11884 11884 D Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. These options vest and become exercisable in their entirety on March 16, 2023. These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Joel Michael Maryles 2022-03-21